Onderbouwing |
Fase II studie afgerond, fase III study ongoing. “The study aims to confirm the data from a Phase II trial in which VAS203 has shown a (2 point) improvement in the extended Glasgow Outcomes Score.” Als de fase 3 studie doelstelling gehaald wordt, 2 punten verschil in GCS na 6 maanden, dan is er zeker meerwaarde. |